DexCom earnings beat by $0.03, revenue topped estimates
ENGLEWOOD, CO—Leslie J. Parrette, a director at Innospec Inc . (NASDAQ:IOSP), sold a total of $40,420 worth of the company’s common stock on May 13, according to a recent SEC filing. The sale involved 446 shares, with prices ranging from $90.5965 to $90.68 per share. Following the transaction, Parrette holds 5,497 shares directly in the $2.2 billion market cap specialty chemicals company. InvestingPro data shows Innospec maintains a strong balance sheet with more cash than debt and a healthy current ratio of 2.73.
The shares were sold through a broker to settle tax withholding obligations related to the vesting of time-based restricted stock units. According to InvestingPro, Innospec demonstrates solid financial health with liquid assets exceeding short-term obligations and a low debt-to-equity ratio of 0.04. InvestingPro subscribers have access to 10 additional key insights about IOSP’s financial position and growth prospects.
In other recent news, Innospec Inc. reported its first-quarter 2025 earnings, highlighting a decline in revenue and a slight miss on earnings per share (EPS) expectations. The company’s revenue was $440.8 million, which was below the forecasted $462 million, and EPS was reported at $1.42, missing the anticipated $1.44. Despite these results, Innospec maintains a strong, debt-free balance sheet and continues to invest in research and development. In a separate development, Innospec’s shareholders recently elected three Class III directors and approved executive compensation during the annual shareholder meeting. Additionally, the appointment of the company’s independent registered public accounting firm for 2025 was ratified. These developments reflect Innospec’s ongoing commitment to governance and transparency. The company has also increased its dividend by 10% to $0.84 per share, signaling confidence in its long-term financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.